CD274 and neoplasm: Specifically, CMGCL improved ≈15% tumor inhibition rate than GCL (Figure 7C–E), with more cuproptosis activation and PD‐L1 upregulation at tumor sites (Figure 7F–H), indicating the necessity of CM coating.